公开(公告)号：US20240141437A1

公开(公告)日：2024-05-02

申请号：US18327305

申请日：2023-06-01

Applicant: Genentech, Inc.

Inventor： Sanjeev MARIATHASAN ,  Chi Yung YUEN ,  Zoe June Fergusson ASSAF ,  Carlos Ernesto BAIS ,  Romain Francois BANCHEREAU

IPC: C12Q1/6886 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28 ,  C12Q1/686 ,  C12Q1/6869 ,  A61K39/00

CPC classification number: C12Q1/6886 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2827 ,  C12Q1/686 ,  C12Q1/6869 ,  A61K2039/505 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/158

Abstract: The invention provides methods and compositions for treating urothelial carcinoma in a patient, for example, by administering a treatment regimen that includes a PD-1 axis binding antagonist (e.g., atezolizumab) to the patient as a neoadjuvant or an adjuvant therapy based on the presence or level of ctDNA in a biological sample obtained from the patient. Also provided are compositions (e.g., a PD-1 axis binding antagonist (e.g., atezolizumab), pharmaceutical compositions thereof, kits thereof, and articles of manufacture thereof) for use in treating urothelial carcinoma in a patient.

公开(公告)号：US20230287127A1

公开(公告)日：2023-09-14

申请号：US18160094

申请日：2023-01-26

Applicant: Genentech, Inc.

Inventor： Bryan IRVING ,  Henry CHIU ,  Heather MAECKER ,  Sanjeev MARIATHASAN ,  Sophie M. LEHAR ,  Yan WU ,  Jeanne CHEUNG

IPC: C07K16/28 ,  C07K16/22 ,  A61K39/00 ,  A61K39/395 ,  C07K16/10 ,  A61K31/7068 ,  C07K16/30 ,  A61K45/06

CPC classification number: C07K16/2827 ,  A61K31/7068 ,  A61K39/00 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  C07K16/22 ,  C07K16/28 ,  C07K16/30 ,  C07K16/1063 ,  C07K16/3046 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/71 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/565 ,  C07K2317/567 ,  Y02A50/30

Abstract: The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.

公开(公告)号：US20180371099A1

公开(公告)日：2018-12-27

申请号：US16115343

申请日：2018-08-28

Applicant: Genentech, Inc. ,  Foundation Medicine, Inc.

Inventor： Richard BOURGON ,  David FABRIZIO ,  Gregg FINE ,  Garrett M. FRAMPTON ,  Priti HEGDE ,  Sanjeev MARIATHASAN ,  Philip J. STEPHENS ,  James Xin SUN ,  Roman YELENSKY

IPC: C07K16/28 ,  A61K39/395 ,  G16H50/30 ,  G16H20/10

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on somatic mutation levels of genes of the invention (e.g., somatic mutation levels in a tumor sample obtained from the patient).

公开(公告)号：US20130253175A1

公开(公告)日：2013-09-26

申请号：US13786206

申请日：2013-03-05

Applicant: GENENTECH, INC.

Inventor： Tim BEAUMONT ,  Mark Jeroen KWAKKENBOS ,  Eric J. BROWN ,  John Hiroshi MORISAKI ,  Wouter L.W. HAZENBOS ,  Sanjeev MARIATHASAN ,  Kimberly KAJIHARA ,  Yi XIA

IPC: C07K16/12

CPC classification number: G01N33/5091 ,  C07K16/1271 ,  C07K16/1278 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  G01N33/6854 ,  G01N33/6893 ,  G01N2469/10 ,  G01N2800/26

Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.

公开(公告)号：US20200031936A1

公开(公告)日：2020-01-30

申请号：US16655495

申请日：2019-10-17

Applicant: Genentech, Inc.

Inventor： Priti HEGDE ,  Marcin KOWANETZ ,  Gregg FINE ,  Sanjeev MARIATHASAN ,  Richard BOURGON

IPC: C07K16/28 ,  C12Q1/6886 ,  G01N33/574

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor-infiltrating immune cells in a tumor sample obtained from the patient) and/or based on the determination of a tumor sample subtype.

公开(公告)号：US20190309071A1

公开(公告)日：2019-10-10

申请号：US16437402

申请日：2019-06-11

Applicant: Genentech, Inc.

Inventor： Sanjeev MARIATHASAN ,  Christina SCHIFF ,  Sujata NARAYANAN

IPC: C07K16/28 ,  C07K14/705 ,  A61P35/02

Abstract: The present invention relates to the treatment of cancers, such as a prostate cancer (e.g., castration-resistant prostate cancer (CRPC)). More specifically, the invention concerns the treatment of human patients having a prostate cancer (e.g., CRPC, e.g., metastatic CRPC) with a combination therapy including an PD-1 axis binding antagonist and an antiandrogen.

公开(公告)号：US20190085087A1

公开(公告)日：2019-03-21

申请号：US16192008

申请日：2018-11-15

Applicant: Genentech, Inc.

Inventor： Priti HEGDE ,  Luciana MOLINERO ,  Sanjeev MARIATHASAN ,  Shannon TURLEY ,  Jillian ASTARITA ,  Rafael CUBAS ,  Yagai YANG

IPC: C07K16/28 ,  G01N33/574 ,  A61P35/00

Abstract: The invention provides methods for identifying an individuals with a disease or disorder who is less likely to respond to immunotherapy alone, the method comprising determining the presence of a stromal gene signature in a sample from the individual, said signature comprising one or more of FAP, FN1, MMP2, PDGFRB, or THY, wherein an increase in the level of expression of the one or more genes in the stroma gene signature relative to a median level identifies an individual for treatment with an immunotherapy and with a suppressive stromal antagonist. In some aspects, the invention provides methods for treating an individual displaying the stromal gene signature. In other aspects, the invention provides kits for determining the presence of a stroma gene signature in a sample from an individual.

公开(公告)号：US20150322153A1

公开(公告)日：2015-11-12

申请号：US14538072

申请日：2014-11-11

Applicant: GENENTECH, INC.

Inventor： Bryan IRVING ,  Henry CHIU ,  Heather MAECKER ,  Sanjeev MARIATHASAN ,  Sophie M. LEHAR ,  Yan WU ,  Jeanne CHEUNG

IPC: C07K16/28 ,  A61K39/395 ,  C07K16/30 ,  A61K45/06 ,  A61K31/7068

CPC classification number: C07K16/2827 ,  A61K31/7068 ,  A61K39/00 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/1063 ,  C07K16/22 ,  C07K16/28 ,  C07K16/30 ,  C07K16/3046 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/71 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/423 ,  Y02A50/489 ,  Y02A50/492 ,  A61K2300/00

Abstract: The present application relates to anti-PD-L1 antibodies, which have therapeutic use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.

Abstract translation: 本申请涉及抗PD-L1抗体，其具有用于增强T细胞功能以上调细胞介导的免疫应答和用于治疗T细胞功能障碍性疾病（包括感染（例如急性和慢性））和肿瘤的治疗用途 免疫。

公开(公告)号：US20240060135A1

公开(公告)日：2024-02-22

申请号：US17937102

申请日：2022-09-30

Applicant: Genentech, Inc.

Inventor： Li-Fen LIU ,  Sanjeev MARIATHASAN ,  Chi Yung YUEN ,  Mahrukh HUSENI

IPC: C12Q1/6886 ,  A61P35/00 ,  C07K16/28 ,  G01N33/574

CPC classification number: C12Q1/6886 ,  A61P35/00 ,  C07K16/2827 ,  G01N33/57484 ,  C07K2317/24 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N2333/5421

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer (e.g., bladder cancer (e.g., UC) or kidney cancer (e.g., RCC)). The invention provides methods of identifying an individual having a cancer who is likely to respond to treatment with an anti-cancer therapy comprising a PD-L1 axis binding antagonist, methods for selecting a therapy for an individual having a cancer, methods of identifying an individual having a cancer who is less likely to respond to treatment with an anti-cancer therapy comprising a PD-L1 axis binding antagonist monotherapy, methods of monitoring the response of an individual having a cancer to treatment with an anti-cancer therapy comprising a PD-L1 axis binding antagonist, and methods of treating an individual having cancer, based on expression levels of a biomarker of the invention (e.g., one or more genes set forth in any one of Tables 1-7, e.g., IL8).

公开(公告)号：US20210032345A1

公开(公告)日：2021-02-04

申请号：US16854707

申请日：2020-04-21

Applicant: Genentech, Inc.

Inventor： Bryan IRVING ,  Henry CHIU ,  Heather MAECKER ,  Sanjeev MARIATHASAN ,  Sophie M. LEHAR ,  Yan WU ,  Jeanne CHEUNG

IPC: C07K16/28 ,  C07K16/30 ,  A61K31/7068 ,  A61K39/395 ,  A61K45/06 ,  C07K16/10 ,  C07K16/22 ,  A61K39/00

Abstract: The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.